Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes

被引：0
|
作者：
Slomski, Anita
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2022年 / 328卷 / 09期
关键词：
D O I：
10.1001/jama.2022.14696
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：817 / 817
页数：1
相关论文
共 50 条
  • [31] Comparative risk of infection of medications used for type 2 diabetes
    Zapata-Bravo, Estefania
    Douros, Antonios
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [32] Dapagliflozin in Patients With Type 2 Diabetes and Established Cardiovascular Disease: Hypotension and Volume-related Safety
    de Bruin, Tjerk W.
    Leiter, Lawrence A.
    Cefalu, William T.
    Gause-Nilsson, Ingrid
    Johnsson, Eva
    Parikh, Shamik J.
    [J]. CIRCULATION, 2013, 128 (22)
  • [33] Efficacy and safety of dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension
    Cefalu, W.
    Leiter, L.
    De Bruin, T.
    Gause-Nilsson, I.
    Sugg, J.
    Parikh, S.
    [J]. DIABETOLOGIA, 2012, 55 : S305 - S305
  • [34] Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes
    Fioretto, Paola
    Avogaro, Angelo
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (05) : 517 - 527
  • [35] Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis
    Memon, Rahat A.
    Akbariromani, Hanieh
    Vohra, Rimsha R.
    Kundi, Hayan
    Saleem, Rao Faraz
    Ghaffari, Muhammad Abuzar
    Haas, Donald
    Khan, Areeba
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [36] Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease
    Leiter, L. A.
    Cefalu, W. T.
    de Bruin, T. W. A.
    Xu, J.
    Parikh, S.
    Johnsson, E.
    Gause-Nilsson, I.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (08): : 766 - 774
  • [37] Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
    Sonesson, Christian
    Johansson, Peter A.
    Johnsson, Eva
    Gause-Nilsson, Ingrid
    [J]. CARDIOVASCULAR DIABETOLOGY, 2016, 15
  • [38] Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
    Christian Sonesson
    Peter A. Johansson
    Eva Johnsson
    Ingrid Gause-Nilsson
    [J]. Cardiovascular Diabetology, 15 (1)
  • [39] Long-term Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes, Cardiovascular Disease, and Hypertension
    Cefalu, William T.
    Gause-Nilsson, Ingrid Ami
    De Bruin, Tjerk W. A.
    Sugg, Jennifer E.
    Parikh, Shamik J.
    Johnsson, Eva
    [J]. DIABETES, 2014, 63 : A286 - A286
  • [40] Dapagliflozin Lowers Blood Pressure in Patients with Type 2 Diabetes
    Sjostrom, David
    Ptaszynska, Agata
    List, James F.
    Johnsson, Eva
    [J]. DIABETES, 2014, 63 : A613 - A613
12345